We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Here’s what I’d have now by investing £1,000 in AstraZeneca shares 5 years ago

AstraZeneca shares have soared over five years, making them one of the FTSE 100’s biggest successes. But what if I’d bought this stock in mid-June 2018?

| More on:
Playful senior couple in aprons dancing and smiling while preparing healthy dinner at home

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

Some investors see the UK stock market as a backwater of old-economy businesses. Yet it also includes a few outstanding global outfits, such as biopharma group AstraZeneca (LSE: AZN). Anyone owning these shares over the past five years has made out like a bandit.

The shares soar

I don’t own any stock in this great British success story. But how I wish I’d held AstraZeneca stock for many years. Since the global financial crisis of 2007-09, the share price has pushed relentlessly higher.

Should you buy AstraZeneca Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

Here’s how it has performed over eight periods:

One week-2.1%
One month-4.1%
Three months+6.6%
Six months+1.3%
One year+18.1%
Two years+37.9%
Three years+40.4%
Five years+111.3%

Apart from recent weakness, the path of the AstraZeneca share price is clear. Over six periods ranging from three months to five years, the stock has produced positive returns.

Even better, it has more than doubled in a half-decade — a period when the FTSE 100 lost 0.7%. What’s more, these figures exclude cash dividends, which recently started rising at the group.

Happy shareholders

Based on Thursday’s closing price of 11,686p, the stock is 8.9% below its 52-week high of 12,828.45p, hit on 8 March. But its strength means that it’s also 23% above its 52-week low of 9,499.21p, set on 20 October 2022.

These strong returns over sustained periods have made AstraZeneca one of the best performers among large-cap shares. Today, the group is worth £178.4bn, making it the second-largest company on the London stock market.

Moreover, its bumper return of +111.3% in five years makes it the FTSE 100’s second-best performer over this period. Brilliant.

Investing five years ago

Let’s say I had the foresight, skill or luck to invest, say, £1,000 in AstraZeneca stock five years ago. How much would I be sitting on today?

A five-year return of 111.3% would boost my initial investment to £2,113 today. But what about those dividends I mentioned earlier? Here are the group’s cash payouts for the last five financial years:

Year20222021202020192018
Total dividend$2.90$2.87$2.80$2.80$2.80

As an multinational corporation, AstraZeneca payouts out dividends in US dollars. Over the past five years, cash dividends total $14.17. Converted into pounds sterling at the current exchange rate of $1.2775 to £1, this comes to £11.09.

Investing £1,000 in mid-2018 would have bought me roughly 19 AstraZeneca shares. Total dividends paid on this shareholding over five years come to £210.71.

Now I have my answer. Buying £1,000 of this FTSE 100 star’s shares in mid-June 2018 would be worth £2,323.71 today. That’s a handsome return of 132.4%.

I won’t buy this stock now

Finally, AstraZeneca stock trades at a super-premium rating to the wider FTSE 100. It has a price-to-earnings ratio of 48.13, which is about four times the Footsie’s rating.

Also, the current dividend yield of 2.1% a year is well below the index’s yearly cash yield of 3.7%. This is a bit too pricey for me, despite AstraZeneca’s ongoing success and future prospects. And in any event, a lack of cash also prevents me from buying the shares today!

Cliff D'Arcy has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services, such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool, we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young black female footballer training on stadium pitch
Investing Articles

How has this FTSE 250 share surged ANOTHER 7% today?

Applied Nutrition shares have soared on Monday after another brilliant trading update. So what's the FTSE 250 company's secret?

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

The stock market game you’re actually playing (and why you might be losing)

Our writer recounts a painful experience of making a rash stock market decision based on emotions, not logic – and…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Why is EasyJet stock suddenly a takeover target for US investors?

Andrew Mackie looks at easyjet shares jumping on US takeover talk — but is this a genuine re-rating or just…

Read more »

Young Black woman looking concerned while in front of her laptop
Investing Articles

Have investors got BT shares all wrong?

BT shares spiked during the 1990s telecom boom, then struggled for two decades. Harvey Jones says it's the future that…

Read more »

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

Looking for buying opportunities in June? Here’s 1 to consider from my Stocks and Shares ISA

The conflict in Iran is making one of the investments in Stephen Wright’s Stocks and Shares ISA volatile. But could…

Read more »

Row of blue European Union flags in Brussels.
Investing Articles

After crashing 13.7% today, is Wise now a stock market bargain at 805p?

Wise was one of the biggest fallers on the UK stock market today. What on earth is going on with…

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

At 8% is this eye-popping FTSE 100 dividend yield simply too good to be true?

The dividend yield is to die for, but the share price is lacking in life. Harvey Jones examines whether this…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

UK investors are piling into this legendary S&P 500 growth stock while it’s down 50%

This US growth stock fell from $240 to $80 amid AI disruption fears. And investors are now aggressively buying it…

Read more »